Results 81 to 90 of about 137,652 (287)

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Low-dose versus standard-dose intravenous immunoglobulin in generalized myasthenia gravis: a prospective single-center cohort study

Frontiers in Neurology
BackgroundGeneralized myasthenia gravis (gMG) is commonly treated with high-dose intravenous immunoglobulin (IVIG), typically at cumulative doses near 2 g/kg, during clinical worsening.
Haocheng Luo, Li Dong, Li Yang, Yufei Deng, Chaoyue Zhang, Xuxiang Zhang, Liqing Hu, Zhenyu Wu, Xiaojun Yang, Qilong Jiang   +9 more
doaj   +1 more source

PREDNISONE THERAPY SAFETY FOR TREATMENT OF PATIENTS WITH MIX OF TUBERCULOSIS AND HIV-INFECTION

Инфекция и иммунитет, 2014
. The study of prednisone safety for treatment of TB mixed with HIV-infection has been conducted. Two groups of patients were compared. The first group was consisted of 88 patients who were treated by prednisone and standard tuberculosis therapy, the ...
G. V. Maksimov, S. L. Mukomolov, A. K. Ivanov   +2 more
doaj   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

American Journal of Hematology, EarlyView.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima, Margaret Mei‐Kay Wong, Jesus Gonzalez‐Lugo, Susan M. Geyer, Ali Alsugair, Maria Sirenko, Kimberly J. Langer, Terra L. Lasho, Christy Finke, Jun Choi, Maher Abdul‐Hay, Gary Ho, Mark R. Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi, William J. Hogan, Mithun V. Shah, Aref Al‐Kali, Kebede H. Begna, Naseema Gangat, Antoine N. Saliba, Ronald S. Go, Tariq Kewan, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Kenneth J. Warrington, Megan Sullivan, Kaaren K. Reichard, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Nathan Punwani, Mary Riwes, Joseph P. McGuirk, Elizabeth F. Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, James Foran, Matthew J. Koster, Mrinal M. Patnaik, David B. Beck, Hassan B. Alkhateeb, Abhishek A. Mangaonkar   +48 more
wiley   +1 more source

Oral cyclophosphamide treatment for clinical periocular inflammation of unknown origin

Oman Journal of Ophthalmology
This study outlines a scenario involving unilateral periocular inflammation exhibited resistance to conventional immunomodulatory therapy (IMT) and biologic response modifying agents, which was successfully managed with oral cyclophosphamide monotherapy.
Arash Maleki, Stephen D. Anesi, Peter Y. Chang, C. Stephen Foster   +3 more
doaj   +1 more source

Kimura’s disease with membranoproliferative glomerulonephritis: a case report with literature review

Renal Failure, 2019
Background: Kimura's disease is a rare disease and its etiology is still unclear. Here we reported a case with lymphadenopathy complicated with secondary membranoproliferative glomerulonephritis.
Sensen Su, Xin Chen, Jia Li, Jinyu Yu, Li Zhang   +4 more
doaj   +1 more source

Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm

American Journal of Hematology, EarlyView.
ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt, Christopher S. Wichman, Alyssa Bouska, Moataz Ellithi, Michael Haddadin, Javeed Iqbal, James E. Talmadge, Lori J. Maness, Krishna Gundabolu   +8 more
wiley   +1 more source

Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review

, 2016
Stefano Paolo Beltrametti,1 Aurora Ianniello,2 Clara Ricci3 1Department of Rheumatology, S. Andrea Hospital, Vercelli, 2Rheumatology Outpatient Clinic, Novara, 3Primula Multimedia S.p.A, Pisa, Italy Abstract: To date, rheumatoid arthritis (RA) remains ...
Ricci C, Beltrametti SP, Ianniello A
core  

Prednisone-dependent asthma: inflammatory indices in induced sputum.

, 1999
The kinetics of changes in inflammatory indices in induced sputum from eight prednisone dependent asthmatics whose minimum clinical maintenance and exacerbation doses were known were investigated.
Pizzichini, MM, Clelland, L, Pavord, Ian, Pizzichini, E, Dolovich, J, Hargreave, FE, Pavord, I, Efthimiadis, A   +7 more
core   +1 more source

Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre Syndrome (MYHRS, MIM #139210) is a rare, multisystem connective tissue disorder caused by recurrent heterozygous gain‐of‐function pathogenic variants in the SMAD4 gene, a key player in TGF‐β signaling and a regulator of extracellular matrix homeostasis.
Alessandro De Falco, Alfonso Manuel D'Alessio, Nicola Brunetti‐Pierri   +2 more
wiley   +1 more source